AutoZone is a great company with a volatile stock, but it's worth keeping an eye one for value in AZO stock after earnings. More
Ascena Retail Group Inc (ASNA) Posts In-Line Earnings
Ascena Retail Group (ASNA) posted its quarterly earnings results after hours late Monday, which its profit meeting Wall Street's expectations. More
Why Shopify Inc (US) Stock Is Too Dangerous to Buy
SHOP stock had a great run over the course of the first nine months of 2017, but the first wave of Shopify euphoria seems to be winding down. More
Vertex Pharmaceuticals’ (VRTX) Strong Quant Score Make it a Buy
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) is a member of the 350 company Biotechnology GICS industry group, which is a segment of the 782 company GICS Health Care sector. The market value of VRTX is $35.6 billion which falls in the top 10% of its industry group. The stock's current Portfolio Grader score places it 32 among the 350 companies in this industry group, positioning it among the leaders; in the top quartile of the sector with a ranking of 102 among the 782 companies in the sector, and number 591 in the nearly 5,000 company Portfolio Grader universe. More
MLP & Strategic Equity Fund (MTP) a Sell on Flagging Sales Growth
MLP & Strategic Equity Fund (NASDAQ:MTP) ranks in the top 10% of its industry group, Biotechnology, and in the top 10% of its sector group, Health Care, with a market value of $36.9 billion. From an investment attractiveness vantage point, MTP is ranked squarely in the bottom quartile of the sector with a ranking of 638 among the 782 companies in the sector; the stock's Portfolio Grader ranking currently places it 279 among the 350 companies in this industry group, a position that is well below-average and number 3,833 in the 5000 company Portfolio Grader company universe. More
Why Citigroup Inc Stock Will Blast Through the $75 Level
Citigroup has been doing well this year, but a larger breakout could be in the cards for C stock. If not, strong support sits near by. More
Regeneron Pharmaceuticals (REGN) a Hold on Vapid Quant Score
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) is classified as a component of the 350 company Biotechnology GICS industry group, which is part of the 782 company GICS Health Care sector. REGN's market value is $40.1 billion which places it in the top decile in its industry group. The current Portfolio Grader ranking for REGN puts it 188 among the 350 companies in this industry group, giving it a lower than average position; in the third quartile of the sector with a ranking of 428 among the 782 companies in the sector, and number 2,601 in the nearly 5,000 company Portfolio Grader universe. More
